Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN(a)-PreEvent
2025-520554-11-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Sep 2025
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity and atherosclerotic disease comparing Olpasiran with Placebo (2 arms). Planned start Sep 2025; status: authorised.
02
Drugs
olpasiran
03
Conditions
cardiac morbidityatherosclerotic disease
Beyond the preview
Go deeper on 2025-520554-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520554-11-00.